[go: up one dir, main page]

WO2010115947A3 - Acide alpha-lipoïque à libération prolongée - Google Patents

Acide alpha-lipoïque à libération prolongée Download PDF

Info

Publication number
WO2010115947A3
WO2010115947A3 PCT/EP2010/054623 EP2010054623W WO2010115947A3 WO 2010115947 A3 WO2010115947 A3 WO 2010115947A3 EP 2010054623 W EP2010054623 W EP 2010054623W WO 2010115947 A3 WO2010115947 A3 WO 2010115947A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipoic acid
alfa
prolonged
release
ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/054623
Other languages
English (en)
Other versions
WO2010115947A2 (fr
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Alida Agostini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valpharma International SpA
DIFASS SA
Original Assignee
Valpharma International SpA
DIFASS SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma International SpA, DIFASS SA filed Critical Valpharma International SpA
Publication of WO2010115947A2 publication Critical patent/WO2010115947A2/fr
Publication of WO2010115947A3 publication Critical patent/WO2010115947A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La présente invention concerne une préparation ayant un profil de libération modifiée sous la forme de comprimés bicouches pour l'administration par voie orale d'acide α-lipoïque, de carnosine, de zinc et autres ingrédients appropriés pour l'optimisation des effets des ingrédients chez des patients atteints de neuropathies périphériques interdépendantes et de neuropathie diabétique.
PCT/EP2010/054623 2009-04-08 2010-04-08 Acide alpha-lipoïque à libération prolongée Ceased WO2010115947A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000073A ITFI20090073A1 (it) 2009-04-08 2009-04-08 Acido alfa-lipoico a rilascio prolungato.
ITFI2009A000073 2009-04-08

Publications (2)

Publication Number Publication Date
WO2010115947A2 WO2010115947A2 (fr) 2010-10-14
WO2010115947A3 true WO2010115947A3 (fr) 2010-12-09

Family

ID=41226364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/054623 Ceased WO2010115947A2 (fr) 2009-04-08 2010-04-08 Acide alpha-lipoïque à libération prolongée

Country Status (2)

Country Link
IT (1) ITFI20090073A1 (fr)
WO (1) WO2010115947A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10413526B2 (en) 2015-03-31 2019-09-17 Kolinpharma S.P.A. Composition for the treatment of neuropathies and/or neuropathic pain
TR202014936A2 (tr) * 2020-09-21 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Alfa li̇poi̇k asi̇t ve en az bi̇r b vi̇tami̇ni̇ i̇çeren bi̇r çi̇ft katmanli farmasöti̇k tablet

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20040034030A1 (en) * 2000-11-03 2004-02-19 Chronorx Llc Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
WO2007019540A2 (fr) * 2005-08-08 2007-02-15 Medical Research Institute Preparation d'acide alpha-lipoique a liberation controlee contenant un compose inositol
WO2008015535A2 (fr) * 2006-08-01 2008-02-07 Difass S.A. Composition ayant une activité anti-oxydante et anti-glycante améliorée
EP1949900A2 (fr) * 2007-01-09 2008-07-30 I.P.S. International Products & Services S.r.l. Formulation solide à libération contrôlée pour l'administration orale en tant que sachet monodose et son procédé de préparation
EP2087902A1 (fr) * 2008-02-05 2009-08-12 Bios Line S.p.a. Formules orales conçues pour protéger les voies respiratoires, avec une référence spéciale aux symptômes inflammatoires et néoplastiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034030A1 (en) * 2000-11-03 2004-02-19 Chronorx Llc Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
WO2007019540A2 (fr) * 2005-08-08 2007-02-15 Medical Research Institute Preparation d'acide alpha-lipoique a liberation controlee contenant un compose inositol
WO2008015535A2 (fr) * 2006-08-01 2008-02-07 Difass S.A. Composition ayant une activité anti-oxydante et anti-glycante améliorée
EP1949900A2 (fr) * 2007-01-09 2008-07-30 I.P.S. International Products & Services S.r.l. Formulation solide à libération contrôlée pour l'administration orale en tant que sachet monodose et son procédé de préparation
EP2087902A1 (fr) * 2008-02-05 2009-08-12 Bios Line S.p.a. Formules orales conçues pour protéger les voies respiratoires, avec une référence spéciale aux symptômes inflammatoires et néoplastiques

Also Published As

Publication number Publication date
ITFI20090073A1 (it) 2010-10-09
WO2010115947A2 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2012034079A3 (fr) Formes pharmaceutiques de type macrolides
MX348491B (es) Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
WO2009133352A3 (fr) Composition lipidique
WO2008146178A3 (fr) Nouvelle forme posologique de comprimé
WO2011115969A3 (fr) Procédé de fabrication d'une forme posologique multiphasique à dissolution rapide, lyophilisée
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
WO2010127205A3 (fr) Formulations de combinaison de médicament à dose fixe
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
IL266097A (en) Citric acid acid salt of (R)-5-((E)-2-(pyrrolidine-3-yl)vinyl)pyrimidine, a pharmaceutical preparation containing the salt, use of the salt in the production of a medicine, salt for use, and method of production
WO2009068708A3 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
MX338975B (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
WO2012074830A3 (fr) Formulation d'acide tranexamique à libération modifiée
WO2012092486A3 (fr) Formulations de benzimidazole à libération modifiée
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
WO2010115947A3 (fr) Acide alpha-lipoïque à libération prolongée
CL2013001684A1 (es) Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico.
IL205044A (en) Derivatives of (5-acetylamino-biphenyl-3-yl) acetic acid, pharmaceutical preparations containing them and their use in the preparation of a drug for the treatment of mammals for the modulation of gamma-secretase and for the treatment of mammals in diseases associated with high levels of beta-42
WO2010142400A3 (fr) Compositions à base d'oligosaccharides de chitosane
IL218069A (en) Oligoscride compounds, drug, pharmaceutical, and compound for its use in therapy
WO2012091425A3 (fr) Composition contenant, comme principe actif, un analogue de 4-hydroxytamoxifène ou un sel pharmaceutiquement acceptable de celui-ci, destinée à la prévention ou au traitement des maladies associées au syndrome métabolique
TR200704897A1 (tr) Uzatılmış salım sağlayan gliklazid formülasyonları@
WO2011126327A3 (fr) Composition pharmaceutique présentant des propriétés de libération contrôlée comprenant du mosapride ou de la lévodropropizine et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10721358

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10721358

Country of ref document: EP

Kind code of ref document: A2